Candesartan is an angiotensin\u202fII receptor blocker (ARB) that takes aim at one of the body’s main bloodpressure hormones. Angiotensin\u202fII normally latches onto AT1 receptors on the smooth muscle lining arteries, commanding them to constrict and stimulating the adrenal glands to release aldosterone, which in turn makes the kidneys hoard salt and water. By silently sitting in those same receptors, candesartan blocks the message: vessels stay relaxed, fluid retention falls, and blood pressure eases without the cough that can plague ACE inhibitors.<\/p>\n
After swallowing, the prodrug candesartan cilexetil is rapidly converted in the gut wall to active candesartan. Peak levels arise in 34\u202fhours, and the molecule’s tight receptor binding gives it a terminal halflife of 9\u202fhours yet an antihypertensive effect that spans the full day, making oncedaily dosing convenient.<\/p>\n
In the large LIFE and CHARM trials, candesartan reduced stroke, heartattack, and heartfailure hospitalisations compared with betablockers or placebo. In systolic heartfailure it often joins betablockers and mineralocorticoid antagonists to lighten ventricular wall stress and improve survival.<\/p>\n
Candesartan is well tolerated: dizziness or mild kidney function changes are the main early hiccups, and serum potassium typically rises only modestly. Because it is highly selective, it does not interfere with bradykinin; therefore, angiooedema is rare and lungs stay clear.<\/p>\n
The tablets are filmcoated, scored, and stable up to 30\u202f\u00b0C, making them travel friendly. For people seeking gentle, steadfast bloodpressure control or an ACEinhibitor alternative, candesartan delivers proven cardiovascular protection with minimal lifestyle disruption.<\/p>\n","protected":false},"excerpt":{"rendered":"